NasdaqGS:INSMBiotechs
Did Insmed’s (INSM) ARIKAYCE and BRINSUPRI Surge Just Recast Its Investment Narrative?
In January 2026, Insmed reported strong preliminary 2025 results, with total revenue rising to US$606.4 million from US$363.7 million a year earlier, fueled by ongoing ARIKAYCE momentum and the first full year of BRINSUPRI sales.
Management also laid out an ambitious 2026 roadmap, spotlighting an expected EU launch for BRINSUPRI and multiple late-stage clinical trial readouts that could reshape its product mix.
Next, we’ll examine how Insmed’s rapid ARIKAYCE and BRINSUPRI expansion might...